Inflammatory effects of peritoneal dialysis: Evidence of systemic monocyte activation

Carmelo Libetta, Luca De Nicola, Teresa Rampino, Walter De Simone, Bruno Memoli

Research output: Contribution to journalArticle

Abstract

We evaluated in peritonitis-free patients undergoing continuous ambulatory peritoneal dialysis (CAPD) the release of both interleukin-6 (IL-6) and β-2-microglobulin (β2m) by cultured peripheral blood mononuclear cells (PBMC), as well as the levels of serum amyloid A (SAA), that is, the main hepatic acute phase protein during inflammation. The same measurements were obtained in hemodialysis (HD) patients, uremic non-dialyzed patients (ESRD) and healthy controls (CON). In CAPD, IL-6 production from PBMC was markedly increased in comparison to the control value (600.7 ± 104.3 vs. 14.2 ± 3.6 pg x 106 PBMC/24 hr, P <0.005). Similarly, a striking enhancement of the PBMC release of β2m was detected in CAPD with respect to CON (10.1 ± 2.6 vs. 0.063 ± 0.013 μg/3 x 106 PBMC/24 hr, P <0.001). Also, the SAA levels were significantly greater in CAPD patients (21.3 ± 8.7 μg/dl) than in controls (3.14 ± 0.17 μg/dl, P <0.05). Analogous increases of both IL-6 and β2m cell releases, as well as of SAA levels, were observed in HD patients. No difference concerning the three parameters was detected between CON and ESRD. In conclusion, CAPD induces per se PBMC activation with an enhanced release of both IL-6 and β2m; this is associated to higher levels of SAA. These systemic inflammatory effects are comparable to those observed in HD patients indicating that CAPD is similar to HD in terms of biocompatibility of the treatment.

Original languageEnglish
Pages (from-to)506-511
Number of pages6
JournalKidney International
Volume49
Issue number2
Publication statusPublished - 1996

Fingerprint

Continuous Ambulatory Peritoneal Dialysis
Peritoneal Dialysis
Serum Amyloid A Protein
Monocytes
Blood Cells
Renal Dialysis
Interleukin-6
Interleukin-2
Chronic Kidney Failure
Acute-Phase Proteins
Peritonitis
Inflammation
Liver

ASJC Scopus subject areas

  • Nephrology

Cite this

Inflammatory effects of peritoneal dialysis : Evidence of systemic monocyte activation. / Libetta, Carmelo; De Nicola, Luca; Rampino, Teresa; De Simone, Walter; Memoli, Bruno.

In: Kidney International, Vol. 49, No. 2, 1996, p. 506-511.

Research output: Contribution to journalArticle

Libetta, Carmelo ; De Nicola, Luca ; Rampino, Teresa ; De Simone, Walter ; Memoli, Bruno. / Inflammatory effects of peritoneal dialysis : Evidence of systemic monocyte activation. In: Kidney International. 1996 ; Vol. 49, No. 2. pp. 506-511.
@article{63a09eb0386a4180a63501825a1e8aec,
title = "Inflammatory effects of peritoneal dialysis: Evidence of systemic monocyte activation",
abstract = "We evaluated in peritonitis-free patients undergoing continuous ambulatory peritoneal dialysis (CAPD) the release of both interleukin-6 (IL-6) and β-2-microglobulin (β2m) by cultured peripheral blood mononuclear cells (PBMC), as well as the levels of serum amyloid A (SAA), that is, the main hepatic acute phase protein during inflammation. The same measurements were obtained in hemodialysis (HD) patients, uremic non-dialyzed patients (ESRD) and healthy controls (CON). In CAPD, IL-6 production from PBMC was markedly increased in comparison to the control value (600.7 ± 104.3 vs. 14.2 ± 3.6 pg x 106 PBMC/24 hr, P <0.005). Similarly, a striking enhancement of the PBMC release of β2m was detected in CAPD with respect to CON (10.1 ± 2.6 vs. 0.063 ± 0.013 μg/3 x 106 PBMC/24 hr, P <0.001). Also, the SAA levels were significantly greater in CAPD patients (21.3 ± 8.7 μg/dl) than in controls (3.14 ± 0.17 μg/dl, P <0.05). Analogous increases of both IL-6 and β2m cell releases, as well as of SAA levels, were observed in HD patients. No difference concerning the three parameters was detected between CON and ESRD. In conclusion, CAPD induces per se PBMC activation with an enhanced release of both IL-6 and β2m; this is associated to higher levels of SAA. These systemic inflammatory effects are comparable to those observed in HD patients indicating that CAPD is similar to HD in terms of biocompatibility of the treatment.",
author = "Carmelo Libetta and {De Nicola}, Luca and Teresa Rampino and {De Simone}, Walter and Bruno Memoli",
year = "1996",
language = "English",
volume = "49",
pages = "506--511",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Inflammatory effects of peritoneal dialysis

T2 - Evidence of systemic monocyte activation

AU - Libetta, Carmelo

AU - De Nicola, Luca

AU - Rampino, Teresa

AU - De Simone, Walter

AU - Memoli, Bruno

PY - 1996

Y1 - 1996

N2 - We evaluated in peritonitis-free patients undergoing continuous ambulatory peritoneal dialysis (CAPD) the release of both interleukin-6 (IL-6) and β-2-microglobulin (β2m) by cultured peripheral blood mononuclear cells (PBMC), as well as the levels of serum amyloid A (SAA), that is, the main hepatic acute phase protein during inflammation. The same measurements were obtained in hemodialysis (HD) patients, uremic non-dialyzed patients (ESRD) and healthy controls (CON). In CAPD, IL-6 production from PBMC was markedly increased in comparison to the control value (600.7 ± 104.3 vs. 14.2 ± 3.6 pg x 106 PBMC/24 hr, P <0.005). Similarly, a striking enhancement of the PBMC release of β2m was detected in CAPD with respect to CON (10.1 ± 2.6 vs. 0.063 ± 0.013 μg/3 x 106 PBMC/24 hr, P <0.001). Also, the SAA levels were significantly greater in CAPD patients (21.3 ± 8.7 μg/dl) than in controls (3.14 ± 0.17 μg/dl, P <0.05). Analogous increases of both IL-6 and β2m cell releases, as well as of SAA levels, were observed in HD patients. No difference concerning the three parameters was detected between CON and ESRD. In conclusion, CAPD induces per se PBMC activation with an enhanced release of both IL-6 and β2m; this is associated to higher levels of SAA. These systemic inflammatory effects are comparable to those observed in HD patients indicating that CAPD is similar to HD in terms of biocompatibility of the treatment.

AB - We evaluated in peritonitis-free patients undergoing continuous ambulatory peritoneal dialysis (CAPD) the release of both interleukin-6 (IL-6) and β-2-microglobulin (β2m) by cultured peripheral blood mononuclear cells (PBMC), as well as the levels of serum amyloid A (SAA), that is, the main hepatic acute phase protein during inflammation. The same measurements were obtained in hemodialysis (HD) patients, uremic non-dialyzed patients (ESRD) and healthy controls (CON). In CAPD, IL-6 production from PBMC was markedly increased in comparison to the control value (600.7 ± 104.3 vs. 14.2 ± 3.6 pg x 106 PBMC/24 hr, P <0.005). Similarly, a striking enhancement of the PBMC release of β2m was detected in CAPD with respect to CON (10.1 ± 2.6 vs. 0.063 ± 0.013 μg/3 x 106 PBMC/24 hr, P <0.001). Also, the SAA levels were significantly greater in CAPD patients (21.3 ± 8.7 μg/dl) than in controls (3.14 ± 0.17 μg/dl, P <0.05). Analogous increases of both IL-6 and β2m cell releases, as well as of SAA levels, were observed in HD patients. No difference concerning the three parameters was detected between CON and ESRD. In conclusion, CAPD induces per se PBMC activation with an enhanced release of both IL-6 and β2m; this is associated to higher levels of SAA. These systemic inflammatory effects are comparable to those observed in HD patients indicating that CAPD is similar to HD in terms of biocompatibility of the treatment.

UR - http://www.scopus.com/inward/record.url?scp=0030040440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030040440&partnerID=8YFLogxK

M3 - Article

C2 - 8821837

AN - SCOPUS:0030040440

VL - 49

SP - 506

EP - 511

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -